Table 3.

Evaluation of SU11248 combined with doxorubicin compared with monotherapies against 100-mm3 established human breast cancer MX-1 in athymic mice

AgentaDose (mg/kg)Mean tumor volume (mm3 ± SEM) (days)%T/Cb (days)P-valueMean day for tumor to reach 400 mm3TCb (days)
ControlN/A700 ± 70 (14)N/AN/A11
SU1124840267 ± 48 (14)62 (14)0.023120
412 ± 68 (31)
Doxorubicin4362 ± 57 (14)48 (14)0.07 (NS)176
843 ± 167 (31)
SU11248 + doxorubicin
40 + 4
182 ± 34 (14)74 (14)0.00963
52
163 ± 55(31)vs. SU11248: 60 (31)0.01
vs. Doxorubicin: 81 (31)0.001
  • a SU11248 given p.o. once daily to study end; doxorubicin given i.v. every other day for three doses.

  • b T/C, tumor growth inhibition, where T is the mean tumor volume of the treated group and C is the mean tumor volume of the control group on the designated day. TC, tumor growth delay, median time (days) for the treated tumors to reach 400-mm3 volume minus the median time for control group to reach 400 mm3 in volume.